Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2021

Aug 13, 2021

SELL
$3.8 - $4.56 $67,966 - $81,560
-17,886 Closed
0 $0
Q1 2021

May 07, 2021

BUY
$4.33 - $6.63 $203 - $311
47 Added 0.26%
17,886 $82,000
Q4 2020

Feb 12, 2021

SELL
$4.87 - $17.29 $2,493 - $8,852
-512 Reduced 2.79%
17,839 $108,000
Q3 2020

Nov 04, 2020

SELL
$15.08 - $27.04 $6,288 - $11,275
-417 Reduced 2.22%
18,351 $302,000
Q2 2020

Aug 12, 2020

BUY
$14.57 - $23.96 $28,367 - $46,650
1,947 Added 11.57%
18,768 $438,000
Q1 2020

May 04, 2020

BUY
$10.27 - $21.23 $24,750 - $51,164
2,410 Added 16.72%
16,821 $249,000
Q4 2019

Feb 05, 2020

BUY
$8.36 - $23.81 $1,061 - $3,023
127 Added 0.89%
14,411 $295,000
Q3 2019

Nov 08, 2019

SELL
$9.83 - $14.82 $973 - $1,467
-99 Reduced 0.69%
14,284 $140,000
Q2 2019

Aug 13, 2019

BUY
$12.9 - $20.8 $12,616 - $20,342
978 Added 7.3%
14,383 $194,000
Q1 2019

May 06, 2019

SELL
$17.7 - $24.93 $7,699 - $10,844
-435 Reduced 3.14%
13,405 $264,000
Q4 2018

Feb 13, 2019

SELL
$19.05 - $36.45 $2,019 - $3,863
-106 Reduced 0.76%
13,840 $313,000
Q3 2018

Nov 09, 2018

BUY
$34.41 - $44.23 $99,307 - $127,647
2,886 Added 26.09%
13,946 $518,000
Q2 2018

Aug 08, 2018

BUY
$39.21 - $50.29 $25,721 - $32,990
656 Added 6.31%
11,060 $434,000
Q1 2018

May 07, 2018

SELL
$41.7 - $64.16 $18,723 - $28,807
-449 Reduced 4.14%
10,404 $511,000
Q4 2017

Feb 09, 2018

BUY
$28.58 - $49.91 $41,441 - $72,369
1,450 Added 15.42%
10,853 $491,000
Q3 2017

Nov 09, 2017

BUY
$23.08 - $34.92 $217,021 - $328,352
9,403
9,403 $328,000

Others Institutions Holding ASMB

# of Institutions
1
Shares Held
16.3K
Call Options Held
0
Put Options Held
0

About ASSEMBLY BIOSCIENCES, INC.


  • Ticker ASMB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 48,436,900
  • Market Cap $713M
  • Description
  • Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection. It is also deve...
More about ASMB
Track This Portfolio

Track American International Group, Inc. Portfolio

Follow American International Group, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of American International Group, Inc., based on Form 13F filings with the SEC.

News

Stay updated on American International Group, Inc. with notifications on news.